Top-News
Biotechnologie USA

Heron Therapeutics Inc Aktie

Aktie
WKN:  A1XB6K ISIN:  US4277461020 US-Symbol:  HRTX
2,37 $
+0,02 $
+0,85%
2,0853 € 15:42:58 Uhr
Depot/Watchlist
Aktienanzahl *
152,09 Mio.
Marktkapitalisierung *
324,87 Mio. €
Streubesitz
23,29%
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 22.01.2025

Heron Therapeutics Inc News

28.04.25 - PR Newswire
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer PR Newswire
22.04.25 - PR Newswire
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 PR Newswire
27.02.25 - PR Newswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire
13.02.25 - PR Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 PR Newswire
23.12.24 - PR Newswire
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina PR Newswire
03.12.24 - PR Newswire
U.S. District Court Upholds Validity of CINVANTI® Patents
U.S. District Court Upholds Validity of CINVANTI® Patents PR Newswire
12.11.24 - PR Newswire
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance PR Newswire
04.11.24 - PR Newswire
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors PR Newswire
29.10.24 - PR Newswire
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 PR Newswire
10.10.24 - PR Newswire
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids PR ...
25.09.24 - PR Newswire
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire
03.09.24 - PR Newswire
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer PR Newswire
06.08.24 - PR Newswire
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance PR Newswire
30.07.24 - PR Newswire
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire
15.07.24 - PR Newswire
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-​Opioid Policy for Pain Relief Under the OPPS and the ASC ...
02.07.24 - PR Newswire
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire
29.05.24 - PR Newswire
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire
07.05.24 - PR Newswire
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire
24.04.24 - PR Newswire
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire
11.04.24 - PR Newswire
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire

Newssuche

Videos

newspaper
30.04.25 +5,62%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »